CardioCoach: A Two-way Communication System to Coach Elderly Patients With Heart Failure
Study Details
Study Description
Brief Summary
This is an open randomized clinical trial with two study arms. One group, receiving usual care for heart failure, will be compared to another group, receiving usual care plus active telemonitoring interference.
When leaving the hospital, the usual care arm receives a document with a predefined medication scheme and advice for the general practitioner (like it is currently done in usual care).
The telemonitoring interference in the other study arm consists of a smartphone application to register medication intake and to transmit the data of an automatic blood pressure device and a balance to a central platform. The goal is to improve medication uptitration (angiotensin-converting-enzyme inhibitor (ACE-I) and bètablockers (BB)) in heart failure patients and to improve medication compliance.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Telemonitoring group Recieve a smartphone with an application to coach them, a blood pressure monitor and scale. |
Device: Telemonitoring
The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
Other Names:
|
| No Intervention: Control group Control group (usual care, without telemonitoring) |
Outcome Measures
Primary Outcome Measures
- Mean medication doses [3 months]
Mean daily doses of ACE-inhibitors/ARB's, β blokkers and Aldosteron antagonists after 3 months. This is estimated by registration of the types of medication, the corresponding doses and the frequency of intake.
Secondary Outcome Measures
- Medication titration [after month 6]
Mean daily doses of ACE-inhibitors/ARB's, β blokkers and Aldosteron antagonists after 6 months. This is estimated by registration of the types of medication, the corresponding doses and the frequency of intake.
- All-cause mortality [up to month 6]
All-cause mortality
- All cardio related hospitalizations (number and time) [up to month 6]
Arrythmogenic nature Ischemic nature Heart failure nature Valvular/surgical nature Elektrofysiological nature (implantation ICD, CRT,…)
- All heart failure hospitalizations [up to month 6]
Treatment with (whether or not intravenous) diuretic therapy Treatment with hemodynamic guided therapy (vasodilators) Treatment with intravenous inotropics
- Number of medical practitioner-patient contacts [up to month 6]
In hospital (medical record) General practitioner At patient home (Remedus)
- Number of (telephone) contacts, registered by the heart failure nurse [up to month 6]
Number of (telephone) contacts, registered by the heart failure nurse
- Number of (telephone) contacts for the encouragement of medication compliance and parameter (Remedus) [up to month 6]
Number of (telephone) contacts for the encouragement of medication compliance (Remedus)
- Evolution of heart failure and comorbidities [up to month 6]
Blood collection with: kidney function determinations, electrolytes Echo parameters (cardiac output, LVEF, diameters end systolic and diastolic) Weight, length, blood pressure, ECG
- Quality of life according to the HeartQoL questionnaire [day 1, month 6]
Quality of life according to the HeartQoL questionnaire
- Satisfaction survey [month 6]
Satisfaction survey about the received care (anonymous) for the cardiocoach group.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 60
-
Patient has to be followed in Ziekenhuis Oost-Limburg or Jessa Ziekenhuis Hasselt and has to live in the region Genk - Hasselt
-
The patient has to be cognitive strong enough and speak enough Dutch to communicate about their health situation and to understand the smartphone application
-
The diagnosis of systolic heart failure or severe myocardial infarction has to be done during consultation or hospitalization
-
Left ventricular ejection fraction (LVEF) <45%
-
Treatment minimally with ACE-I and BB On the basis of an interview between the heart failure nurse and patient, one will decide if the patient is eligible to join the study. The patient also needs to speak sufficient Dutch to be communicative about his/her medical condition.
Exclusion Criteria:
-
Reversible form of heart failure
-
Heart failure due to severe aortic stenosis
-
At the time of inclusion a eGFR less than 30ml/min/kg
-
Presence of a cardiac resynchronization therapy (CRT) device
-
Active treatment with either ACE-I/ARB or BB
-
Patient that are subscribed in a cardiac revalidation program when leaving the hospital
-
Patients with severe form of COPD (GOLD III)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Ziekenhuis Oost-Limburg | Genk | Belgium | 3600 | |
| 2 | Jessa Ziekenhuis | Hasselt | Belgium | 3500 |
Sponsors and Collaborators
- Hasselt University
- Ziekenhuis Oost-Limburg
- Jessa Hospital
Investigators
- Study Director: Vandervoort Pieter, MD, PhD, Ziekenhuis Oost-Limburg
- Study Director: Paul Dendale, MD, PhD, Jessa Ziekenhuis, Hasselt, Belgium
- Study Director: Jo Ravelingen, Remedus, Aartselaar, Belgium
- Study Director: Peter Van Vooren, Fifthplay, Antwerpen, Belgium
- Study Director: Valerie Storms, PhD, Mobile Health Unit, Hasselt University, Hasselt, Belgium
- Principal Investigator: Lars Grieten, PhD, Mobile Health Unit, Hasselt University, Hasselt, Belgium
- Study Chair: Christophe Smeets, PhD student, Mobile Health Unit, Hasselt University, Hasselt, Belgium
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Cardiocoach